Both are herpes simplex viruses that establish lifelong infection in nerve cells and can reactivate later. The practical differences are mostly about:
Globally, HSV is extremely common. The World Health Organization (WHO) estimates about 3.8 billion people under 50 have HSV-1 and about 520 million people ages 15–49 have HSV-2. Prevalence varies by region, age, and access to testing, so these are broad global estimates, not a prediction for any one country or person.
Key truth: Either virus can infect either location. The CDC notes that HSV-1 can cause genital herpes and HSV-2 can infect the mouth, even though the typical pattern still holds. Location and individual immune response matter as much as the virus type when it comes to day-to-day experience.
Most commonly spreads through skin-to-skin contact with the oral area, including:
HSV-1 can also spread mouth-to-genitals through oral sex, which is a major reason genital HSV-1 exists. Risk is highest during an active oral outbreak, but transmission can still occur when skin looks normal.
Most commonly spreads through:
Practical caveat: HSV spreads through skin contact, so condoms lower risk but do not eliminate it, especially if virus is shedding from areas not covered by a condom. Antiviral suppressive therapy can further reduce transmission risk, particularly for HSV-2.
▶ Opens on YouTube
This is where HSV-1 vs HSV-2 often feels most different in real life. Still, recurrence patterns vary widely. Some people have frequent outbreaks, some have few or none, and stress, illness, friction, sleep, and immune status can all influence what happens.
Classic research found recurrence frequency highest for genital HSV-2 compared with other sites and types, averaging around 0.33 recurrences per month (about 4 per year).
In practice, many clinicians describe a wide range, often higher in the first year after infection and then decreasing over time for many people. Daily suppressive antivirals can reduce outbreak frequency and lower transmission risk.
The CDC states that recurrences are less frequent after the first episode of HSV-1 genital herpes compared with HSV-2, and genital shedding decreases rapidly in the first year.
Widely cited research reports genital HSV-1 recurrence rates around ~1.3 per year in the first year and ~0.7 per year in the second year.
Translation: If someone says "I have genital HSV-1 and I basically never get outbreaks," that's plausible. If someone with HSV-2 says "it comes back a lot," that's also plausible, especially early on. Either way, a low outbreak rate does not guarantee zero transmission, because shedding can occur without symptoms.
Both types can cause:
Pregnancy note: Any new genital herpes infection late in pregnancy can be serious for neonatal risk. This is a "talk to your OB" situation, not a DIY-internet situation. If you are pregnant and think you have a new outbreak, seek urgent medical advice.
Immune status note: People who are immunocompromised can have more severe or persistent symptoms and may need different management plans. If lesions are severe, spreading, or not healing, get medical care.
A swab (often PCR) of a fresh lesion can tell you:
Timing matters. Swabs work best when taken early, ideally within 48 hours of lesion appearance, because viral levels drop as sores heal.
Blood tests do not tell you the infection site (oral vs genital). They only indicate past exposure:
Important caveats: Antibodies can take weeks to develop after a new infection, so early testing can be falsely negative. Also, some type-specific HSV-2 IgG results at low index values can be false positives, and confirmatory testing may be recommended depending on the assay and the result.
There is no cure, but antivirals (such as acyclovir, valacyclovir, or famciclovir) can:
Because genital HSV-1 tends to recur and shed less, some people with genital HSV-1 do not need, or do not choose, daily suppressive therapy the way some HSV-2 patients do. Decisions are individualized and often depend on outbreak frequency, partner status, pregnancy plans, and personal preference.
| Feature | HSV-1 | HSV-2 |
|---|---|---|
| Most common site | 🗣 Mouth (cold sores) | Genitals |
| Can infect other site? | ✓ Yes (genital HSV-1 via oral sex) | ✓ Yes (oral HSV-2 can occur, but is less common) |
| Global prevalence | ~64% under age 50 | ~13% ages 15–49 |
| Genital recurrences | 🔸 Less frequent on average (~0.7–1.3 per year after year 1) | 🔴 More frequent on average (~4 per year; often higher in year 1) |
| How commonly acquired | Often in childhood via saliva or kissing (varies by region) | Usually via sexual contact |
| Suppressive therapy | Less commonly needed for genital HSV-1, but can be used if outbreaks or anxiety are significant | Often used for frequent recurrences and to reduce transmission risk |
HSV-1 and HSV-2 comparison based on CDC and WHO summaries and peer-reviewed clinical data.
HSV-1 and HSV-2 are not "good herpes vs bad herpes." They are two common viruses that spread through skin contact, establish lifelong latency in nerves, and sometimes reactivate.
The real difference most people feel is recurrence pattern and typical location, not morality, cleanliness, or worth.
Want to understand which type you might have or how it could affect you? Use our HSV calculators above to explore your specific risk profile, and consider confirming questions about symptoms, testing, or partner protection with a clinician.
Use our evidence-based calculators to estimate your personal STD risk.